Video
Dr. Slovin on an Ongoing Study With Degarelix Leuprolide in Prostate Cancer
Author(s):
Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.
Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.
This is a prospective randomized trial investigating 900 patients who received over 1 year of a GnRH agonist or a GnRH antagonist, explains Slovin. It is open to patients who are newly diagnosed with metastatic disease or patients who might be undergoing definitive radiation therapy and may have the need for upfront or neoadjuvant hormonal ablation.
According to Slovin, this trial will take time to accrue. It is multinational study, so there is a vigorous effort to complete this trial within the next 2 to 3 years.
